Building on five decades of manufacturing heritage from ROVI, the company now operates with a sharpened focus on its role as a specialized contract development and manufacturing organization. CEO Javier López-Belmonte noted that the rebranding effort is designed to capture the firm's evolution into a modern partner capable of balancing high-volume production with the personalized service of a family-led business.
ROIS Unveils New Brand Identity and Website at CPHI Milan 2026
With five manufacturing sites spanning Europe and the United States, ROIS is marking its transition into an independent CDMO by launching a comprehensive new brand identity at CPHI Milan 2026. The rollout includes a revamped corporate website and a redesigned exhibition experience highlighting the firm's expanded global sterile fill-finish capabilities.
ROIS currently manages over 800 million units of annual capacity, specializing in complex injectables such as biologics, biosimilars, and mRNA-based therapies. The company’s technical infrastructure includes high-containment OEB5 facilities, lyophilization, and cytotoxic manufacturing, serving clients across more than 75 international markets. Attendees at CPHI Milan can view the new identity firsthand at booth 10C49 through October 8, where the company is showcasing its integrated service model and global reach.
Comments (0)
No comments yet. Be the first!